Front Row Advisors LLC Avadel Pharmaceuticals PLC Transaction History

Front Row Advisors LLC

  • $271 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 13, 2018
SELL
$4.08 - $7.14 $1,489 - $2,606
-365 Closed
0 $0
Q2 2018

Jul 31, 2018
BUY
$5.89 - $7.78 $94 - $124
16 Added 4.58%
365 $2,000
Q1 2018

May 21, 2018
BUY
$6.76 - $11.7 $1,859 - $3,217
275 Added 371.62%
349 $3,000
Q4 2017

Feb 01, 2018
BUY
$8.03 - $11.25 $594 - $832
74
74 $1,000

Others Institutions Holding AVDL

# of Institutions
8
Shares Held
1.07M
Call Options Held
0
Put Options Held
0
View Full List

About AVADEL PHARMACEUTICALS PLC

AVDL Quotes by TradingView
  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $626M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Front Row Advisors LLC Portfolio

Follow Front Row Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Front Row Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Front Row Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email